|
1
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Yu Z, Sanders AJ, Owen S, Cheng S, Yang X
and Jiang WG: Expression of osteoprotegrin is enhanced in lung
cancer tissues and promotes aggressive cellular traits in H3122
lung cancer cells. Anticancer Res. 37:4277–4283. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yano T, Okamoto T, Fukuyama S and Maehara
Y: Therapeutic strategy for postoperative recurrence in patients
with non-small cell lung cancer. World J Clin Oncol. 5:1048–1054.
2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Coello MC, Luketich JD, Litle VR and
Godfrey TE: Prognostic significance of micrometastasis in
non-small-cell lung cancer. Clin Lung Cancer. 5:214–225.
2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yasuda H, Shima N, Nakagawa N, Yamaguchi
K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A,
et al: Osteoclast differentiation factor is a ligand for
osteoprotegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602.
1998.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Weichhaus M, Chung ST and Connelly L:
Osteoprotegerin in breast cancer: Beyond bone remodeling. Mol
Cancer. 14(117)2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Renema N, Navet B, Heymann MF, Lezot F and
Heymann D: RANK-RANKL signalling in cancer. Biosci Rep.
36(e00366)2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Holen I and Shipman CM: Role of
osteoprotegerin (OPG) in cancer. Clin Sci (Lond). 110:279–291.
2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tsukamoto S, Ishikawa T, Iida S, Ishiguro
M, Mogushi K, Mizushima H, Uetake H, Tanaka H and Sugihara K:
Clinical significance of osteoprotegerin expression in human
colorectal cancer. Clin Cancer Res. 17:2444–2450. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shipman CM and Croucher PI:
Osteoprotegerin is a soluble decoy receptor for tumor necrosis
factor-related apoptosis-inducing ligand/Apo2 ligand and can
function as a paracrine survival factor for human myeloma cells.
Cancer Res. 63:912–916. 2003.PubMed/NCBI
|
|
11
|
Weichhaus M, Segaran P, Renaud A, Geerts D
and Connelly L: Osteoprotegerin expression in triple-negative
breast cancer cells promotes metastasis. Cancer Med. 3:1112–1125.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Jia J, Zhou H, Zeng X and Feng S: Estrogen
stimulates osteoprotegerin expression via the suppression of
miR-145 expression in MG-63 cells. Mol Med Rep. 15:1539–1546.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhao Q, Li P, Ma J and Yu X: MicroRNAs in
lung cancer and lung cancer bone metastases: Biomarkers for early
diagnosis and targets for treatment. Recent Pat Anticancer Drug
Discov. 10:182–200. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Saito Y, Suzuki H, Tsugawa H, Nakagawa I,
Matsuzaki J, Kanai Y and Hibi T: Chromatin remodeling at Alu
repeats by epigenetic treatment activates silenced microRNA-512-5p
with downregulation of Mcl-1 in human gastric cancer cells.
Oncogene. 28:2738–2744. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bao B, Ali S, Kong D, Sarkar SH, Wang Z,
Banerjee S, Aboukameel A, Padhye S, Philip PA and Sarkar FH:
Anti-tumor activity of a novel compound-CDF is mediated by
regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS
One. 6(e17850)2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fanini F, Vannini I, Amadori D and Fabbri
M: Clinical implications of microRNAs in lung cancer. Semin Oncol.
38:776–780. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kuo PL, Liao SH, Hung JY, Huang MS and Hsu
YL: MicroRNA-33a functions as a bone metastasis suppressor in lung
cancer by targeting parathyroid hormone related protein. Biochim
Biophys Acta. 1830:3756–3766. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Salgado RA, Snoeckx A, Spinhoven M, Op de
Beeck B, Corthouts B and Parizel PM: Update in non small-cell lung
cancer staging. JBR-BTR. 96:118–122. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Magnet FS, Majorski DS, Callegari J,
Schwarz SB, Schmoor C, Windisch W and Storre JH: Capillary
PO2 does not adequately reflect arterial PO2
in hypoxemic COPD patients. Int J Chron Obstruct Pulmon Dis.
12:2647–2653. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33(e179)2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cao Y, Zhao D, Li P, Wang L, Qiao B, Qin
X, Li L and Wang Y: MicroRNA-181a-5p impedes IL-17-induced nonsmall
cell lung cancer proliferation and migration through targeting
VCAM-1. Cell Physiol Biochem. 42:346–356. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kapinas K, Kessler CB, Ricks T, Gronowicz
G and Delany AM: miR-29 modulates WNT signaling in human
osteoblasts through a positive feedback loop. J Biol Chem.
285:25221–25231. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Connor KM, Hempel N, Nelson KK, Dabiri G,
Gamarra A, Belarmino J, Van De Water L, Mian BM and Melendez JA:
Manganese superoxide dismutase enhances the invasive and migratory
activity of tumor cells. Cancer Res. 67:10260–10267.
2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhuo W, Liu Y, Li S, Guo D, Sun Q, Jin J,
Rao X, Li M, Sun M, Jiang M, et al: Long noncoding RNA GMAN,
Up-regulated in gastric cancer tissues, is associated with
metastasis in patients and promotes translation of ephrin A1 by
competitively binding GMAN-AS. Gastroenterology. 156:676–691.e11.
2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang W, Ma J, Jin F and Liao J:
Hyperbranched polymer drug delivery treatment for lung metastasis
of salivary adenoid cystic carcinoma in nude mice. Exp Ther Med.
14:3105–3111. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Naumnik W, Plonska I, Ossolinska M,
Niklinski J and Naumnik B: Prognostic value of osteoprotegerin and
sRANKL in bronchoalveolar lavage fluid of patients with advanced
non-small cell lung cancer. Adv Exp Med Biol. 1047:1–6.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Weidle UH, Birzele F and Nopora A:
MicroRNAs as potential targets for therapeutic intervention with
metastasis of non-small cell lung cancer. Cancer Genomics
Proteomics. 16:99–119. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kanzaki H, Wada S, Yamaguchi Y, Katsumata
Y, Itohiya K, Fukaya S, Miyamoto Y, Narimiya T, Noda K and Nakamura
Y: Compression and tension variably alter Osteoprotegerin
expression via miR-3198 in periodontal ligament cells. BMC Mol Cell
Biol. 20(6)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhong S, Golpon H, Zardo P and Borlak J:
miRNAs in lung cancer. A systematic review identifies predictive
and prognostic miRNA candidates for precision medicine in lung
cancer. Transl Rese. 230:164–196. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Petrek H and Yu AM: MicroRNAs in non-small
cell lung cancer: Gene regulation, impact on cancer cellular
processes, and therapeutic potential. Pharmacol Res Perspect.
7(e00528)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Xu X, Zhu S, Tao Z and Ye S: High
circulating miR-18a, miR-20a, and miR-92a expression correlates
with poor prognosis in patients with non-small cell lung cancer.
Cancer Med. 7:21–31. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sisay M, Mengistu G and Edessa D: The
RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer
stem cell: Potential targets for anticancer therapy. Onco Targets
Ther. 10:3801–3810. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Theoleyre S, Wittrant Y, Tat SK, Fortun Y,
Redini F and Heymann D: The molecular triad OPG/RANK/RANKL:
Involvement in the orchestration of pathophysiological bone
remodeling. Cytokine Growth Factor Rev. 15:457–475. 2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Brown JM, Corey E, Lee ZD, True LD, Yun
TJ, Tondravi M and Vessella RL: Osteoprotegerin and rank ligand
expression in prostate cancer. Urology. 57:611–616. 2001.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shi W, Qiu W, Wang W, Zhou X, Zhong X,
Tian G and Deng A: Osteoprotegerin is up-regulated in pancreatic
cancers and correlates with cancer-associated new-onset diabetes.
Biosci Trends. 8:322–326. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wu S, Pan Y, Mao Y, Chen Y and He Y:
Current progress and mechanisms of bone metastasis in lung cancer:
A narrative review. Transl Lung Cancer Res. 10:439–451.
2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Mountzios G, Ramfidis V, Terpos E and
Syrigos KN: Prognostic significance of bone markers in patients
with lung cancer metastatic to the skeleton: A review of published
data. Clin Lung Cancer. 12:341–349. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Pitari MR, Rossi M, Amodio N, Botta C,
Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT,
Arbitrio M, et al: Inhibition of miR-21 restores RANKL/OPG ratio in
multiple myeloma-derived bone marrow stromal cells and impairs the
resorbing activity of mature osteoclasts. Oncotarget.
6:27343–27358. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhan FL, Liu XY and Wang XB: The Role of
MicroRNA-143-5p in the differentiation of dental pulp stem cells
into odontoblasts by targeting Runx2 via the OPG/RANKL signaling
pathway. J Cell Biochem. 119:536–546. 2018.PubMed/NCBI View Article : Google Scholar
|
